Independent Medical/Regulatory Reviewer for a Blinded Biopharma Research Packet

We are conducting an academic study of how public biopharma information moves from scientific and regulatory sources into wider media coverage. We need one independent medical or regulatory expert to review a small blinded research packet before it is released to human coders. This is a protocol-quality assignment within the same research pipeline, serving as an independent quality gate before Stage 2 coding. It is not stock picking, investment advice or market prediction. You must not search for or use stock prices, returns, later commercial outcomes, AI-generated ratings, or other coders' answers. You will receive after a paid contract is opened: - a rating manual; - a packet containing 10 cases and 24 contemporaneous source items; - a 10-row review CSV; - a read-only source manifest and integrity hashes. For each case, verify: - clinical phase, endpoint and direction of the evidence; - whether regulatory language is accurately distinguished (designation, advisory recommendation, submission, approval); - whether the company has a direct economic interest in the asset; - whether any source is truncated, ambiguous or medically misleading; - whether the packet can be coded without later knowledge; - any correction required before release. Deliverables: 1. Completed 10-row medical-review CSV with all identifiers unchanged. 2. Concise evidence-based notes for every requested correction. 3. A signed statement confirming that no market outcomes, later commercial outcomes, AI-generated ratings or other coders' answers were consulted. Do not assign F/A/N ratings and do not rewrite the source evidence unless a specific correction is documented. Payment is for a complete independent protocol review, not agreement with the project owner. This contract does not promise any later coding work. Preferred qualifications: - MD, PharmD, PhD in a biomedical field, or substantial regulatory/clinical development experience; - experience interpreting clinical trials and FDA/EMA materials; - strong written English; - no participation in our earlier Stage 1 biopharma rating test. Fixed price: US$125. Expected effort: 2–3 hours. Due within three calendar days after contract activation. Please answer these screening questions in your proposal: 1. State your degree and the clinical-development, regulatory or evidence-review work most relevant to this assignment. 2. In two to four sentences, distinguish an FDA designation, an advisory committee recommendation, a marketing application submission and formal FDA approval. 3. Give one example of why a statistically significant biomarker result may not justify calling a trial clinically successful. 4. Confirm that you did not participate in our earlier biopharma blind-rating test and can avoid all stock-price, return and later-outcome information. 5. Confirm that you can preserve CSV identifiers and return the review within three calendar days. Do not complete the review as part of your proposal. The packet will be provided only after a paid contract is opened.